SCHEMBL432161

SCHEMBL432161

CCCCCSc1nc(N)nc2nc[nH]c12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAK1 Q13153 1/20 0.66
CYP1A2 P05177 5/20 0.62
CYP3A4 P08684 4/20 0.62
CYP2C19 P33261 4/20 0.62
CYP2D6 P10635 3/20 0.62
CYP2C9 P11712 2/20 0.62
ALDH1A1 P00352 1/20 0.62
TOP2A P11388 1/20 0.62
HPGD P15428 1/20 0.62
NUDT1 P36639 1/20 0.62
HIF1A Q16665 1/20 0.62
HSD17B10 Q99714 1/20 0.62
MAP3K5 Q99683 1/20 0.60
CDK1 P06493 4/20 0.59
CCNB1 P14635 4/20 0.59
CDK2 P24941 4/20 0.59
CCNA2 P20248 3/20 0.59
CCNA1 P78396 3/20 0.59
PIN1 Q13526 2/20 0.57
POLB P06746 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16758710 0.84 MAP3K5 (0.69) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL1725584 0.80 PAK1 (1.00) PAK1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL24846509 0.79 CYP1A2 (0.88) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL5144928 0.79 XDH (0.56) PAK1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL8642694 0.78 PAK1 (0.97) PAK1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL10927540 0.78 PAK1 (0.97) PAK1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL9465617 0.78 PAK1 (0.97) PAK1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL432160 0.78 PAK1 (0.48) PAK1CYP1A2CYP3A4CYP2C19CYP2D6
SCHEMBL24846512 0.77 CYP1A2 (1.00) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9
SCHEMBL94363 0.76 MAP3K5 (1.00) CYP1A2CYP3A4CYP2C19CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318700-B2 Lung-targeted drugs THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-11-27 US disclosed
US-20120122818-A1 LUNG-TARGETED DRUGS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-05-17 US disclosed
US-8101745-B2 Conjugate cidofovir, idoxuridine, vidarabine, trifluridine, acyclovir, famciclovir penciclovir, valacyclovir, ganciclovir, antiviral, antimicrobial, cancer drug of interest to glycerol ethers or glycerol phosphate ethers THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-01-24 US disclosed
US-20080221061-A1 Lung-Targeted Drugs THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2008-09-11 US disclosed
WO-2001064693-A1 PHOSPHONATE NUCLEOTIDE COMPOUND MITSUBISHI PHARMA CORPORATION (JP) 2001-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221061-A1 Lung-Targeted Drugs DGKG, GK, PHOSPHO1 PAK1 1138/4885CYP1A2 4057/4885CYP3A4 3814/4885
US-20120122818-A1 LUNG-TARGETED DRUGS DGKG, GK, PHOSPHO1 PAK1 1138/4885CYP1A2 4057/4885CYP3A4 3814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.